

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

U 016364-6

SERIAL NO.

10/585,623

APPLICANT

Fenglin CHEN

FILING DATE

GROUP

July 11, 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA	5,468,619	11/1995	Senyei et al.	
	AB	5,281,522	01/1994	Senyei et al.	
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL	02/42769	05/2002	WO		X
	AM	83/00877	03/1983	WO		
	AN	28 36 362	03/1980	DE		X
	AO	9-218202	08/1997	JP		X
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AQ	English Abstract: American Chemical Society. Ogasawara, M. et al. "Clinical Significance of β 2 Glycoprotein I Dependent Aanticardiolipin Antibody, Lupus Anticoagulant and Antinuclear Antibodies in Patients with Recurrent Miscarriages" <i>Reproductive Immunology</i> (1998) Vol. 10, pp 272-276
	AR	English Abstract: American Chemical Society. Kano, T. et al. "The Incidence of Endometriosis and Adenomyosis in Patients with Habitual Abortion in Relation to Immunological Abnormalities" <i>Nippon Gakkaizasshi</i> (1997) Vol. 42, No. 2, pp113-118
	AS	Zhang, S. "Methods for Detecting Antinuclear Antibodies and Clinical Significance thereof" <i>Journal of Nephrophathy, Dialysis and Kidney Transplantation</i> (1995) Vol. 4, Issue 5, pp 495-497

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.